Martin Philipp Feth

Summary

Affiliation: Sanofi-Aventis Deutschland GmbH

Publications

  1. ncbi Challenges in the development of hydrate phases as active pharmaceutical ingredients--an example
    Martin P Feth
    Sanofi Aventis Deutschland GmbH, Chemical Development, Industriepark Hochst, Frankfurt am Main, Germany
    Eur J Pharm Sci 42:116-29. 2011
  2. ncbi New technology for the investigation of water vapor sorption-induced crystallographic form transformations of chemical compounds: a water vapor sorption gravimetry-dispersive Raman spectroscopy coupling
    Martin Philipp Feth
    Sanofi Aventis Deutschland GmbH, Research and Development, LGCR, Chemical Development, Process and Particle Development Group, 65926 Frankfurt, Germany
    J Pharm Sci 100:1080-92. 2011

Detail Information

Publications2

  1. ncbi Challenges in the development of hydrate phases as active pharmaceutical ingredients--an example
    Martin P Feth
    Sanofi Aventis Deutschland GmbH, Chemical Development, Industriepark Hochst, Frankfurt am Main, Germany
    Eur J Pharm Sci 42:116-29. 2011
    ..g. particle size d 90 value<20 ?m, water content and crystallographic phase corresponding to desired form 1 of SAR474832)...
  2. ncbi New technology for the investigation of water vapor sorption-induced crystallographic form transformations of chemical compounds: a water vapor sorption gravimetry-dispersive Raman spectroscopy coupling
    Martin Philipp Feth
    Sanofi Aventis Deutschland GmbH, Research and Development, LGCR, Chemical Development, Process and Particle Development Group, 65926 Frankfurt, Germany
    J Pharm Sci 100:1080-92. 2011
    ..This is especially interesting for physically and chemically labile hydrate phases...